Interestingly, CD4+ cells derived from the peripheral blood of patients with MS show a differential expression of the VPAC1 and VPAC2 receptors, compared to those from healthy controls, depending on the activation status of the cells. Here, VIPR2 is linked to myeloid sarcoma.